Prospective in silico study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT.

ABSTRACT:

Purpose

We aim to determine the feasibility and dosimetric benefits of a novel MRI-guided IMRT dose-adaption strategy for human papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPC).

Materials/methods

Patients with locally advanced HPV+ OPC underwent pre-treatment and in-treatment MRIs every two weeks using RT immobilization setup. For each patient, two IMRT plans were created (i.e. standard and adaptive). The prescription dose for the standard plans was 2.12 Gy/fx for 33 fractions to the initial PTV. For adaptive plans, a new PTV_adaptive was generated based on serial MRIs in case of detectable tumor shrinkage. Prescription dose to PTV_adaptive was 2.12 Gy/fx to allow for maximum dose to the residual disease. Any previously involved

SUBMITTER: Mohamed ASR 

PROVIDER: S-EPMC6019867 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature